- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04242797
Central Mechanisms of Calmare: an fMRI Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pain can be either useful or harmful. Acute pain conveys information to the brain about real or potential damage that can productively lead to avoidance or treatment of the damage. However, chronic pain, which extends beyond these useful purposes, becomes a potentially debilitating inconvenience. Estimations based on surveys report that as many as 33% of Americans suffer from chronic pain, with a significant portion being unable to successfully manage it.
The current means to treating chronic pain include: surgery, drug therapy, physical therapy, psychological intervention, and others. Unfortunately, despite these options, many people continue to suffer from a chronic pain condition. Neuropathic pain, or pain caused by nervous system damage, is particularly hard to treat. Drug therapy and surgery have relatively low success rates and undesirable side effects. Thus, there is a need for additional research and new treatment methods for neuropathic pain patients.
The Calmare device was designed as one such means to treat chronic neuropathic pain. It works through electrostimulation of the skin near the pain site, and, according to recent studies, has significantly reduced chronic neuropathic pain in most subjects (Majithia et al., 2016).
Previous studies of Calmare effectiveness have defined the success of treatment as the reduction of reported pain levels by the patient. Though useful, these studies fail to provide an objective measurement of pain reduction and fail to discover the mechanisms by which it occurs. In addition, previous studies have been unable to perform a true double-blind experiment in which the placebo effect was entirely accounted for. The pilot study takes a step toward filling this gap by performing a double blind, randomized single-treatment trial comparing Calmare efficacy to traditional transcutaneous electrical nerve stimulation (TENS) efficacy. The ten-treatment study examines the durability of the pain relief for 12 weeks after the treatment period.
The goal of these studies is two-fold: first, to use fMRI before and after a full therapeutic Calmare treatment course to determine the extent to which Calmare affects the connectivity of the pain centers of the brain, and second, to determine whether traditional TENS or Calmare is more effective in reducing neuropathic chronic pain. The Calmare treatment is administered in a double-blind fashion with neither the technician, nor the subject knowing whether the TENS or the Calmare is being administered. The investigator's hypothesis is that Calmare therapy decreases subject pain through a central mechanism that will be manifest in decreased functional connectivity of the brain's pain centers. The degree to which this happens is determined by comparing the decrease in pain intensity, as reported by the patient, with the difference in fMRI BOLD temporal correlations between pain centers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Provo, Utah, United States, 84602-1018
- BYU MRI Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- They must have suffered from a diagnosed peripheral neuropathy (diabetic, chemotherapy induced, or other) for a minimum of 6 months.
- At the time of the study they must experience pain greater than or equal to 5 on a visual analog pain scale from 0-10, with 0 being "no pain" and 10 being "the worst imaginable pain."
Exclusion Criteria:
- pregnancy
- a history of epilepsy or brain damage
- presence of a serious psychiatric disorder (e.g. schizophrenia, manic-depressive psychosis, primary major depression)
- multiple sources of chronic pain (e.g. a chronic pain condition other than a peripheral neuropathy or more than one site of neuropathies)
- a skin condition that would prevent application of skin electrodes
- latex allergy
- severe arrhythmia or any form of equivalent heart disease
- history of myocardial infarction or ischemic heart disease within the past 6 months
- celiac plexus block or other neurolytic pain control treatment within the past 4 weeks
- state of active withdrawal from drugs and/or alcohol
- ineligible for fMRI due to metal implants, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Calmare
Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
|
Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at ~47 Hz.
|
Active Comparator: Traditional TENS
Single- or ten-dose treatments on consecutive weekdays, 30 minutes each.
|
Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analaog Scale (VAS) Pain Score Changes
Time Frame: The intra-subject change in VAS score from pre-Rx baseline a) after the 30-minute treatment and b) again the next day (pilot), or a) after each of the ten 30-minute treatments and b) 6- and 12-weeks from end of treatment (extended)
|
Change from baseline in VAS score, which is marked on a line labeled 0 on the left (no pain) and 10 on the right (the most exquisite pain imaginable).
|
The intra-subject change in VAS score from pre-Rx baseline a) after the 30-minute treatment and b) again the next day (pilot), or a) after each of the ten 30-minute treatments and b) 6- and 12-weeks from end of treatment (extended)
|
Washington Neuropathic Pain Scale (WNPS) Pain Score Changes
Time Frame: The intra-subject change in ten WNPS pain scores from baseline after the 30-minute Rx and again the next day (pilot) or after each of the ten 30-minute Rxs and 6- and 12-weeks from end of Rx period (extended)
|
Change from baseline in each of ten WNPS scores, which are marked boxes have integral values of 0 on the left (no pain) and 10 on the right (the most exquisite pain imaginable).
|
The intra-subject change in ten WNPS pain scores from baseline after the 30-minute Rx and again the next day (pilot) or after each of the ten 30-minute Rxs and 6- and 12-weeks from end of Rx period (extended)
|
Changes in resting fMRI Correlations
Time Frame: Intra-subject changes in fMRI signals from baseline (taken immediately before first Rx) obtained 30 minutes after first Rx (pilot) or 10th Rx (extended) and again 24 hours later (pilot) or 6-weeks later (extended).
|
Change in temporal correlations of resting fMRI signals from 93 cerebral regions of interest.
|
Intra-subject changes in fMRI signals from baseline (taken immediately before first Rx) obtained 30 minutes after first Rx (pilot) or 10th Rx (extended) and again 24 hours later (pilot) or 6-weeks later (extended).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David D Busath, M.D., Brigham Young University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F15130
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Neuropathy
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
M.D. Anderson Cancer CenterFoundation for Anesthesia Education and ResearchRecruitingNeuropathy;PeripheralUnited States
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Yale University; University of Manchester; Maastricht University; Ospedale San... and other collaboratorsUnknownPainful Peripheral Neuropathy | Painless Peripheral Neuropathy
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownDiabetic Peripheral Neuropathy
-
Hawler Medical UniversityUnknownDiabetic Peripheral NeuropathyIraq
-
Baylor College of MedicineNeuroMetrix, Inc.RecruitingPain | Neuropathy | Chemotherapy-induced Peripheral NeuropathyUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
Clinical Trials on Calmare
-
Virginia Commonwealth UniversityNational Institute of Nursing Research (NINR)Completed
-
Johns Hopkins UniversityCompleted
-
Brooke Army Medical CenterUnknownLow Back Pain | Peripheral NeuropathyUnited States
-
Virginia Commonwealth UniversityCompletedPain | Neurotoxicity | Peripheral Neuropathy | Cancer-related Problem/ConditionUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedNeuropathyUnited States
-
Johns Hopkins UniversityRecruiting